Clinical Trial Update: Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update reports that Palvella Therapeutics' PTX-022 Phase 2/3 study for Pachyonychia Congenita has completed. The update does not provide eff…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pachyonychia Congenita

Drugs mentioned

• PTX-022

Snippet

Sponsor: Palvella Therapeutics, Inc. | Conditions: Pachyonychia Congenita | Phase 2, Phase 3 | Status: COMPLETED